Chongqing Lummy Pharmaceutical Management

Management criteria checks 2/4

We currently do not have sufficient information about the CEO.

Key information

Rongzhao Qiu

Chief executive officer

n/a

Total compensation

CEO salary percentage	n/a
CEO tenure	3.9yrs
CEO ownership	n/a
Management average tenure	5yrs
Board average tenure	3.9yrs

Recent management updates

Recent updates

Risks To Shareholder Returns Are Elevated At These Prices For Chongqing Lummy Pharmaceutical Co., Ltd. (SZSE:300006)

Feb 27

CEO

Rongzhao Qiu (29 yo)

3.9yrs

Tenure

Mr. Rongzhao Qiu is General Manager of Chongqing Lummy Pharmaceutical Co., Ltd. from June 12, 2020.

Leadership Team

Name	Position	Tenure	Compensation	Ownership
Xue Feng Leng	Deputy General Manager and Vice Chairman	8.2yrs	CN¥487.80k	no data
Dan Cui	Deputy GM	6.2yrs	CN¥359.70k	0.0016% CN¥ 49.0k
Song Lin	Deputy GM & Director	1.4yrs	no data	no data
Rongzhao Qiu	General Manager	3.9yrs	no data	no data
Wen Lai	Financial Director	8.2yrs	no data	no data

5.0yrs

Average Tenure

49yo

Average Age

Experienced Management: 300006's management team is seasoned and experienced (5 years average tenure).

Board Members

Name	Position	Tenure	Compensation	Ownership
Xue Feng Leng	Deputy General Manager and Vice Chairman	8.2yrs	CN¥487.80k	no data
Song Lin	Deputy GM & Director	1.3yrs	no data	no data
Yuan Yuan	Chairman of Supervisory Board	7.3yrs	no data	no data
Xujiang Chen	Independent Director	3.9yrs	CN¥60.00k	no data
Geng Chen	Independent Director	3.9yrs	CN¥60.00k	no data
Jiansheng Liang	Chairman	2.4yrs	CN¥140.20k	no data
Rihua Ou	Director	3.9yrs	no data	no data
Weiyan Tang	Director	3.9yrs	no data	no data
Changbi Li	Independent Director	3.9yrs	no data	no data
Huichuan Xu	Employee Supervisor	10.3yrs	no data	no data
Mingyue Tan	Supervisor	2.4yrs	no data	no data
Hai Run Wang	Director	1.3yrs	no data	no data

3.9yrs

Average Tenure

46yo

Average Age

Experienced Board: 300006's board of directors are considered experienced (3.9 years average tenure).

Chongqing Lummy Pharmaceutical Management

Management criteria checks 2/4

Key information

Recent management updates

Chongqing Lummy Pharmaceutical Co., Ltd., Annual General Meeting, Apr 12, 2024

Less than half of directors are independent

Insufficient new directors

Chongqing Lummy Pharmaceutical Co., Ltd., Annual General Meeting, Apr 15, 2022

Chongqing Lummy Pharmaceutical Co., Ltd., Annual General Meeting, Apr 15, 2022

Recent updates

First quarter 2024 earnings released: CN¥0.004 loss per share (vs CN¥0.003 loss in 1Q 2023)

First quarter 2024 earnings released: CN¥0.004 loss per share (vs CN¥0.003 loss in 1Q 2023)

First quarter 2024 earnings released: CN¥0.004 loss per share (vs CN¥0.003 loss in 1Q 2023)

First quarter 2024 earnings released: CN¥0.004 loss per share (vs CN¥0.003 loss in 1Q 2023)

First quarter 2024 earnings released: CN¥0.004 loss per share (vs CN¥0.003 loss in 1Q 2023)

First quarter 2024 earnings released: CN¥0.004 loss per share (vs CN¥0.003 loss in 1Q 2023)

First quarter 2024 earnings released: CN¥0.004 loss per share (vs CN¥0.003 loss in 1Q 2023)

Chongqing Lummy Pharmaceutical Co., Ltd. to Report Q1, 2024 Results on Apr 24, 2024

Chongqing Lummy Pharmaceutical Co., Ltd., Annual General Meeting, Apr 12, 2024

Full year 2023 earnings released: CN¥0.008 loss per share (vs CN¥0.065 loss in FY 2022)

Risks To Shareholder Returns Are Elevated At These Prices For Chongqing Lummy Pharmaceutical Co., Ltd. (SZSE:300006)

Chongqing Lummy Pharmaceutical Co., Ltd. to Report Fiscal Year 2023 Results on Mar 23, 2024

Less than half of directors are independent

Third quarter 2023 earnings released: EPS: CN¥0 (vs CN¥0.011 in 3Q 2022)

Second quarter 2023 earnings released: CN¥0.048 loss per share (vs CN¥0.021 loss in 2Q 2022)

Full year 2022 earnings released: CN¥0.065 loss per share (vs CN¥0.10 loss in FY 2021)

Third quarter 2022 earnings released: EPS: CN¥0.011 (vs CN¥0.012 loss in 3Q 2021)

Second quarter 2022 earnings released: CN¥0.021 loss per share (vs CN¥0.017 loss in 2Q 2021)

First quarter 2022 earnings: EPS and revenues miss analyst expectations

Insufficient new directors

Chongqing Lummy Pharmaceutical Co., Ltd., Annual General Meeting, Apr 15, 2022

Chongqing Lummy Pharmaceutical Co., Ltd., Annual General Meeting, Apr 15, 2022

Full year 2021 earnings: EPS and revenues miss analyst expectations

First quarter 2021 earnings released: EPS CN¥0.055 (vs CN¥0.01 loss in 1Q 2020)

Full year 2020 earnings released: CN¥0.40 loss per share (vs CN¥0.19 loss in FY 2019)

Changzhou Lummy Qingfeng Pharmaceutical Industry Investment Center (Limited Partnership) agreed to acquire 35% Chengdu Medicom Medical Information Systems Co., Ltd from Chongqing Lummy Pharmaceutical Co., Ltd. (SZSE:300006) for approximately CNY 200 million.

Chongqing Lummy Pharmaceutical Co., Ltd. to Report Fiscal Year 2020 Results on Mar 31, 2021

New 90-day low: CN¥6.65

Hangzhou Bulaisen Pharmaceutical Technology Co., Ltd. signed a share transfer agreement to acquire Sichuan Hezheng Pharmaceutical Co., Ltd. from Chongqing Lummy Pharmaceutical Co., Ltd. (SZSE:300006) for approximately CNY 170 million.

New 90-day low: CN¥7.08

New 90-day high: CN¥8.54

New 90-day high: CN¥8.21

Third quarter earnings released

Chongqing Lummy Pharmaceutical Co., Ltd. to Report Q3, 2020 Results on Oct 28, 2020

First half earnings released

CEO

Tenure

Leadership Team

Average Tenure

Average Age

Board Members

Average Tenure

Average Age